FDA clears narrow use of Lynparza in prostate cancer, continuing ‘shift’ on PARP drugs

FDA clears narrow use of Lynparza in prostate cancer, continuing ‘shift’ on PARP drugs

Submitted by admin on June 1, 2023 - 11:49am
Source: 
BioPharma Dive
News Tags: 
AstraZeneca
Merck
Lynparza
prostate cancer
FDA
Headline: 
FDA clears narrow use of Lynparza in prostate cancer, continuing ‘shift’ on PARP drugs
snippet: 

The Food and Drug Administration on Wednesday approved AstraZeneca and Merck & Co.’s Lynparza for use in certain people newly diagnosed with advanced prostate cancer.

Do Not Allow Advertisers to Use My Personal information